Understanding ACSL4 as a metabolic switch rather than a static oncogenic factor may enable rational design of ferroptosis-enhancing and immunometabolic therapeutic strategies and support biomarker-guided precision medicine in HCC. Here, ACSL4 is linked to hepatocellular carcinoma.